株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

DNAワクチンの世界市場の予測

GLOBAL DNA VACCINE MARKET FORECAST 2017-2025

発行 Inkwood Research 商品コード 560788
出版日 ページ情報 英文 127 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
DNAワクチンの世界市場の予測 GLOBAL DNA VACCINE MARKET FORECAST 2017-2025
出版日: 2017年10月01日 ページ情報: 英文 127 Pages
概要

当レポートでは、DNAワクチンの世界市場について調査し、市場の概要、タイプ・用途・技術・地域別の市場動向および市場予測、市場成長への各種影響要因の分析、競合情勢、市場の将来展望、主要企業のプロファイルなどを包括的にまとめています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の決定要因

  • 市場促進要因
  • 市場阻害要因
  • 市場機会
  • 課題

第5章 市場区分

  • タイプ別
    • 動物用DNAワクチン
    • ヒト用DNAワクチン
  • 用途別
    • ヒト疾患の治療
    • 動物疾患の治療
  • 技術別
    • プラスミドDNAワクチン
    • プラスミドDNAデリバリー

第6章 市場分析

  • ファイブフォース分析
  • 主な購買基準
  • 主要企業
  • 市場機会の指標
  • バリューチェーン分析
  • 規制の枠組み

第7章 地域区分

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 競合環境

  • 戦略イニシアチブ
    • 買収
    • パートナーシップ
    • コラボレーション
    • イノベーション
    • 投資撤退
    • 事業拡大

第9章 企業プロファイル

  • 企業の市場シェア
目次
Product Code: 10292

KEY FINDINGS:

The Global DNA vaccines market is predicted to grow at a CAGR of 44.84%, generating $22172 million by the end of the forecast period of 2017-2025. Factors like increasing investments for third-generation vaccines, increasing adoption in animal healthcare and potential application of these vaccines in identifying growing prevalence of diseases is influencing the market growth.

MARKET INSIGHTS:

The Global DNA Vaccines Market is segmented on the basis of types, technologies, and applications. The types are further segmented into animal DNA vaccine and human DNA vaccine. The market technologies include plasmid DNA vaccines and Plasmid DNA delivery. The market finds its applications for veterinary as well as human diseases. At present, veterinary applications are leading the segment.

REGIONAL INSIGHTS:

The Global DNA vaccines market covers the regions of North America, Asia-Pacific, Europe and rest of world. The North American market is expected to hold a dominant share by the end of the forecast period. The rising prevalence of incessant diseases in countries such as the US and Canada is fueling the market growth. The Asia-Pacific region is expected exhibit the fastest growth between 2017-2025, due to emerging interests in third-generation DNA vaccination, government support, and increasing conduction of clinical trials.

COMPETITIVE INSIGHTS:

Eurogentec S.A, Madison Vaccines Incorporated (MVI), Sanofi, Inovio Pharmaceuticals Inc and Novartis Ag are the leading market players in the global market. The other key market companies include Astellas Pharma Inc, Dendreon Corporation, Eli Lilly And Company, Glaxosmithkline Inc, Merial Limited (Acquired By Boehringer Ingelheim), Merck & Co, Vgxi, Vical Incorporated, Xenetic Biosciences Inc and Zoetis Inc.

TABLE OF CONTENTS

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ACTIVE CLINICAL TRIALS FOR HUMAN DNA VACCINE IS FUELING THE MARKET GROWING POTENTIAL
    • 3.2.2. NORTH AMERICA IS THE GLOBAL LEADER OF DNA VACCINE MARKET
    • 3.2.3. VETERINARY DISEASES LEADS THE APPLICATION SEGMENT OF THE DNA VACCINE MARKET
    • 3.2.4. CANCER TREATMENT ARE AN IMPORTANT FOCUS OF DNA VACCINE CLINICAL TRIALS

4. MARKET DETERMINANTS

  • 4.1. DRIVERS
    • 4.1.1. DNA VACCINES SHOW GREAT PROMISE IN CHECKING THE RISING PREVALENCE OF DISEASE
    • 4.1.2. THIRD GENERATION VACCINATION IS EXPERIENCING A SURGE IN INVESTMENT
    • 4.1.3. INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
  • 4.2. RESTRAINTS
    • 4.2.1. LENGTHY REGULATORY PROCESS
    • 4.2.2. POOR PATENT PROTECTION IN SOME COUNTRIES
  • 4.3. OPPORTUNITIES
    • 4.3.1. TRANSFORMING HEALTHCARE LANDSCAPE
    • 4.3.2. NEW DEVELOPMENTS IN BIOTECHNOLOGY AND NANOTECHNOLOGY
    • 4.3.3. STABLE VACCINES MAKES IT ATTRACTIVE TO STORE AND TRANSPORT
  • 4.4. CHALLENGES
    • 4.4.1. VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE

5. MARKET SEGMENTATION

  • 5.1. MARKET BY TYPE 2017-2025
    • 5.1.1. ANIMAL DNA VACCINE
    • 5.1.2. HUMAN DNA VACCINE
  • 5.2. MARKET BY APPLICATION 2017-2025
    • 5.2.1. HUMAN DISEASE
    • 5.2.2. VETERINARY DISEASE
  • 5.3. MARKET BY TECHNOLOGY 2017-2025
    • 5.3.1. PLASMID DNA VACCINES
    • 5.3.2. PLASMID DNA DELIVERY

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREATS OF SUBSTITUTE PRODUCT
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. KEY BUYING CRITERIA
    • 6.2.1. EFFICACY
    • 6.2.2. COST-EFFECTIVENESS
    • 6.2.3. STABILITY
  • 6.3. KEY MARKET PLAYERS
    • 6.3.1. VICAL INCORPORATED
    • 6.3.2. SANOFI
    • 6.3.3. MERCK AND CORP
    • 6.3.4. GSK
  • 6.4. OPPORTUNITY MATRIX
  • 6.5. VALUE CHAIN ANALYSIS
    • 6.5.1. R&D
    • 6.5.2. MANUFACTURING
    • 6.5.3. RAW MATERIALS
    • 6.5.4. MARKETING, DISTRIBUTION & END USER
  • 6.6. LEGAL, POLICY AND REGULATORY FRAMEWORK

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. INDIA
    • 7.3.2. CHINA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA
    • 7.3.5. REST OF ASIA PACIFIC
  • 7.4. REST OF THE WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPETITIVE LANDSCAPE

  • 8.1. STRATEGIC INITIATIVES
    • 8.1.1. ACQUISITION
    • 8.1.2. PARTNERSHIP
    • 8.1.3. COLLABORATION
    • 8.1.4. INNOVATION
    • 8.1.5. DISINVESTMENT
    • 8.1.6. EXPANSION

9. COMPANY PROFILE

  • 9.1. MARKET SHARE
  • 9.2. ASTELLAS PHARMA INC.
    • 9.2.1. OVERVIEW
    • 9.2.2. PRODUCT PORTFOLIO
    • 9.2.3. SCOT ANALYSIS
    • 9.2.4. STRATEGIC INITIATIVE
  • 9.3. DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
    • 9.3.1. OVERVIEW
    • 9.3.2. PRODUCT PORTFOLIO
    • 9.3.3. SCOT ANALYSIS
    • 9.3.4. STRATEGIC INITIATIVE
  • 9.4. ELI LILLY AND COMPANY
    • 9.4.1. OVERVIEW
    • 9.4.2. PRODUCT PORTFOLIO
    • 9.4.3. SCOT ANALYSIS
    • 9.4.4. STRATEGIC INITIATIVE
  • 9.5. EUROGENTEC S.A
    • 9.5.1. OVERVIEW
    • 9.5.2. PRODUCT PORTFOLIO
    • 9.5.3. SCOT ANALYSIS
    • 9.5.4. STRATEGIC INITIATIVE
  • 9.6. GLAXOSMITHKLINE INC.
    • 9.6.1. OVERVIEW
    • 9.6.2. PRODUCT PORTFOLIO
    • 9.6.3. SCOT ANALYSIS
    • 9.6.4. STRATEGIC INITIATIVES
  • 9.7. INOVIO PHARMACEUTICALS, INC.
    • 9.7.1. OVERVIEW
    • 9.7.2. PRODUCT PORTFOLIO
    • 9.7.3. SCOT ANALYSIS
    • 9.7.4. STRATEGIC INITIATIVE
  • 9.8. MADISON VACCINES INCORPORATED (MVI)
    • 9.8.1. OVERVIEW
    • 9.8.2. PRODUCT PORTFOLIO
    • 9.8.3. SCOT ANALYSIS
  • 9.9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
    • 9.9.1. OVERVIEW
    • 9.9.2. PRODUCT PORTFOLIO
    • 9.9.3. SCOT ANALYSIS
    • 9.9.4. STRATEGIC INITIATIVE
  • 9.10. MERCK & CO.
    • 9.10.1. OVERVIEW
    • 9.10.2. PRODUCT PORTFOLIO
    • 9.10.3. SCOT ANALYSIS
    • 9.10.4. STRATEGIC INITIATIVE
  • 9.11. NOVARTIS AG
    • 9.11.1. OVERVIEW
    • 9.11.2. PRODUCT PORTFOLIO
    • 9.11.3. SCOT ANALYSIS
    • 9.11.4. STRATEGIC INITIATIVE
  • 9.12. SANOFI
    • 9.12.1. OVERVIEW
    • 9.12.2. PRODUCT PORTFOLIO
    • 9.12.3. SCOT ANALYSIS
    • 9.12.4. STRATEGIC INITIATIVE
  • 9.13. VGXI
    • 9.13.1. OVERVIEW
    • 9.13.2. PRODUCT PORTFOLIO
    • 9.13.3. SCOT ANALYSIS
    • 9.13.4. STRATEGIC INITIATIVES
  • 9.14. VICAL INCORPORATED
    • 9.14.1. OVERVIEW
    • 9.14.2. PRODUCT PORTFOLIO
    • 9.14.3. SCOT ANALYSIS
    • 9.14.4. STRATEGIC INITIATIVE
  • 9.15. XENETIC BIOSCIENCES INC.
    • 9.15.1. OVERVIEW
    • 9.15.2. PRODUCT PORTFOLIO
    • 9.15.3. SCOT ANALYSIS
    • 9.15.4. STRATEGIC INITIATIVE
  • 9.16. ZOETIS INC
    • 9.16.1. OVERVIEW
    • 9.16.2. PRODUCT PORTFOLIO
    • 9.16.3. SCOT ANALYSIS
    • 9.16.4. STRATEGIC INITIATIVE

TABLE LIST

  • TABLE 1 GLOBAL DNA VACCINE MARKET BY GEOGRAPHIES 2017-2025 ($ MILLION)
  • TABLE 2 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS
  • TABLE 3 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY
  • TABLE 4 CLINICAL TRIALS FOR HUMANS INVOLVING DNA VACCINES
  • TABLE 5 TEMPERATURE REQUIREMENTS IN PRESERVATION OF VARIOUS VACCINES
  • TABLE 6 GLOBAL DNA VACCINE MARKET BY TYPE 2017-2025 ($ MILLION)
  • TABLE 7 GLOBAL ANIMAL DNA VACCINE MARKET BY GEOGRAPHY 2017-2025($MILLION)
  • TABLE 8 GLOBAL HUMAN DNA VACCINE MARKET BY GEOGRAPHY 2017-2025
  • TABLE 9 GLOBAL DNA VACCINE MARKET BY APPLICATION 2017-2025 ($ MILLION)
  • TABLE 10 GLOBAL HUMAN DISEASES APPLICATION MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
  • TABLE 11 GLOBAL VETERINARY APPLICATION MARKET BY GEOGRAPHY 2017-2025
  • TABLE 12 GLOBAL DNA VACCINE MARKET BY TECHNOLOGY 2017-2025 ($ MILLION)
  • TABLE 13 GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET BY GEOGRAPHY 2017-2025
  • TABLE 14 GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET BY GEOGRAPHY 2017-2025
  • TABLE 15 REGULATIONS TO BE FOLLOWED BEFORE COMMERCIALIZATION
  • TABLE 16 GLOBAL DNA VACCINES MARKET, BY GEOGRAPHIES 2017-2025 ($ MILLION)
  • TABLE 17 NORTH AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • TABLE 18 EUROPE DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • TABLE 19 ASIA PACIFIC DNA VACCINES MARKET 2017-2025 ($ MILLION)
  • TABLE 20 REST OF THE WORLD DNA VACCINES MARKET 2017-2025 ($ MILLION)

FIGURE LIST

  • FIGURE 1 GLOBAL DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 2 NORTH AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 3 GLOBAL DNA VACCINE MARKET IN VETERINARY DISEASES 2017-2025 ($ MILLION)
  • FIGURE 4 SHARE OF TRIALS BY VACCINE TARGET IN 2016
  • FIGURE 5 SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKER IN 2016
  • FIGURE 6 CLINICAL TRIALS OF GENE THERAPY
  • FIGURE 7 GLOBAL DNA VACCINE MARKET SHARE BY TYPE 2016 & 2025 (%)
  • FIGURE 8 GLOBAL DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2017-2025 ($ MILLION)
  • FIGURE 9 GLOBAL DNA VACCINE MARKET IN HUMAN DNA VACCINES 2017-2025($ MILLION)
  • FIGURE 10 GLOBAL DNA VACCINE MARKET SHARE BY APPLICATION 2016 & 2025 (%)
  • FIGURE 11 GLOBAL DNA VACCINES MARKET IN HUMAN DISEASES 2017-2025 ($ MILLION)
  • FIGURE 12 GLOBAL DNA VACCINES MARKET IN VETERINARY APPLICATION 2017-2025 ($ MILLION)
  • FIGURE 13 GLOBAL DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2017-2025 ($ MILLION)
  • FIGURE 14 GLOBAL DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2017-2025 ($ MILLION)
  • FIGURE 15 VALUE CHAIN ANALYSIS FOR DNA VACCINE INDUSTRY
  • FIGURE 16 UNITED STATES DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 17 CANADA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 18 UNITED KINGDOM DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 19 FRANCE DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 20 GERMANY DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 21 SPAIN DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 22 REST OF EUROPE DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 23 INDIA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 24 CHINA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 25 JAPAN DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 26 AUSTRALIA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 27 REST OF ASIA PACIFIC DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 28 LATIN AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 29 MENA DNA VACCINE MARKET 2017-2025 ($ MILLION)
  • FIGURE 30 MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2016
Back to Top